Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Disease
- Therapeutic
- Genome
- Drug Discovery
- Delivery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 227234
U.S. Patent Application Serial No. 08/816,346 entitled 'Chimeric Adenoviral Coat Protein and Methods of Using Same'
U.S. Patent Application Serial No. 08/854,601 entitled 'Multigene HSV Vectors for Cancer Immunotherapy'
U.S. Patent Application Serial No. 08/861,773 entitled 'An Improved Method for the Production of Non-Group C Adenoviral Vectors'
U.S. Patent Application Serial No. 60/047,849 entitled 'Alternately Targeted Adenovirus'
U.S. Patent Application Serial No. 60/049,072 entitled 'Phage Vector and Methods of Use'
U.S. Patent Application Serial No. 60/054,329 entitled.'Targeted HSV Vectors'
The collaboration involves the development of Ad.CD for immunotherapy of cancer based on the delivery of tumor antigen genes. Ad.CD, an adenovirus vector containing the cytosine deaminase ('CD') gene, is designed to convert a nontoxic precursor drug into fluorouracil to effect tumor destruction, either alone or in combination with radiation therapy.
IPSCIO Record ID: 244658
Licensor grants an exclusive, worldwide license under the Ad Interferon-beta Product Licensor Patents and the Ad Interferon-beta Product Technology to develop, research, make, have made, use, have used, sell, offer for sale, import and have sold the Ad Interferon-beta Product in the Cancer Field and the Beta Interferon Field .
For the Manufacturing License, Licensor will provide a transferable, limited license or subiicense as the case may be under the Licensor Technology and the Licensor Patents to manufacture such Clinical Vectors and Commercial Vectors to the extent necessary to enable Licensee to manufacture quantities of the Clinical Vectors and Commercial Vectors that otherwise would have been supplied by Licensor to Licensee under this Agreement, solely for use and application by Licensee for the uses and applications in the Territory that would be permitted under this Agreement with respect to such Clinical Vectors and Commercial Vectors purchased from Licensor.
Licensor grants a license, with right to grant sublicenses, under the Licensor Technology and the Licensor Patents to research, develop, manufacture, have manufactured, use, import, export, offer to sell or sell Products in the Territory.
Licensor grants a nonexclusive, worldwide license, with right to sublicense to Contractors permitted under this Agreement, to the Licensed Technology, other than the Applied Licensor Technology, as designated in the applicable Project Plan and Budget, and under any Licensor Patents, other than the Exhausted Licensed Patents and the Exempted Licensed Patents, as designated in the applicable Project Plan and Budget, which would, but for this license grant, be infringed by Licensees performance of its Development Tasks solely as necessary for performance of Licensees Development Tasks during and in the course of any approved Development Project.
In addition to the other rights granted under this Agreement, Licensor hereby grants an option to acquire a license, with the right to grant sublicenses, to Licensor Technology, that is not otherwise designated as Applied Licensor Technology in the applicable Project Plan and Budget, and under any and all Targeted Patents, that are not designated as Exhausted Licensor Patents or as Exempted Licensor Patents in the applicable Project Plan and Budget.
AAV Interferon-beta Product means a Product incorporating the Beta Interferon Gene and any AAV Vector as the delivery platform.
AAV Vector means an adeno-associated viral vector useful or potentially useful for the delivery of Genes to human cells.
Ad Interferon-beta Product means the Product incorporating the Beta Interferon Gene and an Ad Vector that is the subject of the Ad Interferon-beta Project.
Ad Vector means an adenoviral vector useful or potentially useful for the delivery of Genes to human cells.
Cancer Field means the treatment or prevention in humans of one or more cancers through the use or application of AAV Vectors or Ad Vectors.
IPSCIO Record ID: 279353
With this new commercialization license, Licensor grants to the Licensee of Japan an exclusive, license under the Licensor Technology and Licensors interest in the Joint Technology, to make, have made use, sell and otherwise commercialize Collaboration Products for all uses in the Field in the Territory.
CD vector shall mean either a DART Vector or a GV11 Vector, in either case that incorporates the nucleic acid sequence for cytosme deaminase and does not incorporate any other nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit.
Gene Therapy shall mean the introduction of a nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit into a person for therapeutic purposes by in vivo introduction for incorporation into cells of such person, or by ex vivo introduction into cells for transfer into a person.
IPSCIO Record ID: 367305
Patent rights, proprietary information and know-how relate to our HyperAcute immunotherapy technology.
The patents include
Radioisotope concentrator methods and compositions;
Radiation enhanced gene therapy for treatment of tumors;
Differential inactivation of nucleic acids by chemical modification;
Herpes simplex virus amplicon mini-vector gene transfer system;
Methods and compositions for inducing complement destruction of tissue;
Human suppressor TRNA oligonucleotides and methods of use for same;
DNA Methylation associated with genetic instability in retroviral vector producing cells;
HSV-ATM Vector for ataxia-telangiectasia gene therapy;
Activation of ganciclovir for generating anti-tumor responses;
ATM Vector;
Dual adenoviral delivery of transgenes.
The inventions and Know-how include
Polyphosphokinase gene to attempt gene therapy by creating polymers of radioactive phosphate;
Sodium iodide symporter related efforts;
Improved Herpes simplex vectors;
Humanized T4 endonuclease V gene therapy for UV photoproduct damage;
Animal model of cancer in a(1,3)galactosyltransferase knockout mice.
IPSCIO Record ID: 202789
In the original sublicense agreement Sublicensor grants to Sublicensee a non-exclusive, perpetual, non-cancellable sublicense to manufacture, have manufactured, use and research Licensed Products and to otherwise exploit Licensed Technology, but only for research purposes and not for commercial use, in the Field throughout the Territory, including the right to grant further sublicenses, it being intended that the sublicense herein granted covers all rights of Sublicensor in the Licensed Subject Matter in the Field and in the Territory.
The original License the University grants to this agreement Licensor, an exclusive license to manufacture, have manufactured, use and/or sell the Licensed Produces, to practice any method, process or procedure and to otherwise exploit the Licensed Subject Matter, within the Licensed Territory for use within the field.
The original agreement license property is
Patent and technology rights for U.S. and Foreign Patent Application entitled
•Methods and Compositions for the Selective Inhibition of Gene Expression
•Australia Serial No. 15704/92; Canada Serial No. 2108144; European Serial No. 92908663-5; and
•Methods and Compositions for Retroviral Vector Mediated Transduction, Continuation-in-part U.S. Serial No. 960513; and
•Methods and Compositions for the Selective Inhibition of Gene Expression, Continuation-in-part U.S. Serial No. 987235; and
•Recombinant p53 Adenovirus Methods and Compositions, Continuation-in-part U.S. Serial No. 145826;
•An Adenovirus Supervector System, Continuation-in-part patent has not been filed yet; and
•Recombinant p53 Adenovirus Methods and Compositions, U.S. Serial No. 224232; and
•Methods and Compositions Comprising DNA Damaging Agents and p53, Continuation-in-part patent has not been filed yet; and
•Use of Lectins for the Delivery and Translocation of Genetic Material Across Cell Membranes, patent has not filed yet; and
•Reconstruction of a-FAS/APO-1 Mediated-Apoptosis in Human Cancer Cells by Adenovirus-Mediated transduction of the Wildtype p53 Gene, patent has not filed yet
Cancer can spread when cells’ natural cancer suppression functions are impaired. The tumor suppressor gene called Tumor Suppressor Candidate 2, or TUSC2 (which was formerly known as FUS1) has been shown to affect both cell proliferation and apoptosis. TUSC2 is a pan-kinase inhibitor, which means that it has the ability to inhibit multiple kinase receptors, such as EGFR and platelet-derived growth factor receptor, or PDGFR. TUSC2 is frequently inactivated early in the development of lung cancer, and loss of TUSC2 expression in NSCLC is associated with significantly worse overall survival compared to patients with normal TUSC2 expression. Many types of cancer cells, including approximately 85% of NSCLC cells, lack expression of TUSC2.
IPSCIO Record ID: 243413
The VTA technology is a proprietary therapeutic platform designed to specifically target tumor vasculature and subsequently destroy the tumor with various attached therapeutic agents.
